{
  "symbol": "CELG-RI",
  "year": 2023,
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.1864,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.196
  },
  "top_positive": [
    {
      "sent": "Our ESG strategy focuses on (i) operating with effective governance and the highest ethical standards, and seeking transparency and dialogue with our stakeholders to improve our understanding of their needs, (ii) fostering an environment of inclusion and belonging and build a globally diverse workforce to drive equitable advancement and outcomes for all, (iii) around the globe, improve access to our innovative therapies and promote health equity to improve health outcomes for populations disproportionately affected by serious diseases and (iv) understand our responsibility to create a maximum positive impact while minimizing our environmental footprint while leveraging sustainability to drive innovation, build resiliency and manage nonfinancial risks.",
      "score": 0.9747
    },
    {
      "sent": "Our ESG strategy focuses on (i) operating with effective governance and the highest ethical standards, and seeking transparency and dialogue with our stakeholders to improve our understanding of their needs, (ii) fostering an environment of inclusion and belonging and build a globally diverse workforce to drive equitable advancement and outcomes for all, (iii) around the globe, improve access to our innovative therapies and promote health equity to improve health outcomes for populations disproportionately affected by serious diseases and (iv) understand our responsibility to create a maximum positive impact while minimizing our environmental footprint while leveraging sustainability to drive innovation, build resiliency and manage nonfinancial risks.",
      "score": 0.9747
    },
    {
      "sent": "Our ESG strategy focuses on (i) operating with effective governance and the highest ethical standards, and seeking transparency and dialogue with our stakeholders to improve our understanding of their needs, (ii) fostering an environment of inclusion and belonging and build a globally diverse workforce to drive equitable advancement and outcomes for all, (iii) around the globe, improve access to our innovative therapies and promote health equity to improve health outcomes for populations disproportionately affected by serious diseases and (iv) understand our responsibility to create a maximum positive impact while minimizing our environmental footprint while leveraging sustainability to drive innovation, build resiliency and manage nonfinancial risks.",
      "score": 0.9747
    }
  ],
  "top_negative": [
    {
      "sent": "8 HEMATOLOGY PHASE I PHASE II PHASE III APPROVED INDICATIONS Additional Indications OPDIVO --Hematologic Malignancies Investigational Compounds alnuctamab BCMA TCE --Relapsed/Refractory Multiple Myeloma Anti-SIRP\u03b1 -- Hematologic Malignancies BCMA ADC^ --Relapsed/Refractory Multiple Myeloma BCMA NKE --Relapsed/Refractory Multiple Myeloma BET Inhibitor (CC-90010)^ --Hematologic Malignancies CD33 NKE --Relapsed/Refractory Multiple Myeloma CD47xCD20 --Non-Hodgkin's Lymphoma CK1\u03b1 Degrader --Hematologic Malignancies GPRC5D CAR-T --Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009)^ --Relapsed/Refractory Acute Myeloid Leukemia iberdomide^ --1L Diffuse Large B-cell Lymphoma --3L+ Follicular Lymphoma --Relapsed/Refractory Non-Hodgkin Lymphoma --Large B-cell Lymphoma Additional Indications ABECMA \u00aa --1-4L+ Multiple Myeloma BREYANZI --3L+ Chronic Lymphocytic Leukemia --3L+ Follicular Lymphoma --3L+ Marginal Zone Lymphoma --3L+ Mantle Cell Lymphoma ONUREG --Low-to-Intermediate risk MDS OPDIVO \u00aa + EMPLICITI \u00aa --Relapsed/Refractory Multiple Myeloma REBLOZYL \u00aa --A-Thalassemia SubQ IDHIFA --1L Acute Myeloid Leukemia Investigational Compounds A/I CELMoD (CC-99282)^ --Relapsed/Refractory Non-Hodgkin Lymphoma BET Inhibitor (BMS-986158) --Hematologic Malignancies iberdomide --Newly-Diagnosed Multiple Myeloma Additional Indications ABECMA \u00aa --3-5L Multiple Myeloma INREBIC --MF Previously treated with Ruxolitinib REBLOZYL \u00aa --1L TD MDS Associated Anemia --1L TD MF Associated Anemia Investigational Compounds iberdomide --2L+ Multiple Myeloma mezigdomide (CC-92480) --2L+ Multiple Myeloma ABECMA --5L+ Relapsed/Refractory Multiple Myeloma --4L+ Relapsed/Refractory Multiple Myeloma BREYANZI --2L Large B-cell Lymphoma --3L+ Large B-cell Lymphoma EMPLICITI \u00aa + POMALYST/IMNOVID --Relapsed/Refractory Multiple Myeloma EMPLICITI \u00aa + REVLIMID --Relapsed/Refractory Multiple Myeloma IDHIFA -- Relapsed/Refractory Acute Myeloid Leukemia INREBIC --Myelofibrosis ONUREG --Post-Induction Acute Myeloid Leukemia Maintenance OPDIVO \u00aa --Advanced Hodgkin Lymphoma POMALYST/IMNOVID --Multiple Myeloma --Relapsed/Refractory Multiple Myeloma --AIDS related Kaposi Sarcoma --HIV-negative Kaposi Sarcoma REBLOZYL \u00aa --Transfusion-Dependent Beta-Thalassemia --MDS Previously treated with ESA REVLIMID --1L Multiple Myeloma --Mantle Cell Lymphoma --MDS --Multiple Myeloma --Previously treated Follicular Lymphoma --Relapsed/Refractory Adult T-cell Leukemia/Lymphoma SPRYCEL --1L CML --Pediatric ALL --Refractory CML 9 ONCOLOGY PHASE I PHASE II PHASE III APPROVED INDICATIONS Additional Indications OPDIVO \u00aa --Solid Tumors OPDIVO \u00aa + YERVOY \u00aa --Solid Tumors Investigational Compounds AHR Antagonist^ --Solid Tumors Anti-CCR8^ --Solid Tumors Anti-ILT4^ \u00aa --Solid Tumors AR-LDD^ --Solid Tumors Anti-NKG2A^ --Solid Tumors Claudin 18.2 ADC \u00aa --Advance Solid Tumors CD3xPSCA Bispecific --Solid Tumors DGK Inhibitor --Solid Tumors JNK Inhibitor --Solid Tumors LSD1 Inhibitor^ --Solid Tumors MAGE A4/8 TCER \u00aa --Solid Tumors SHP2 Inhibitor \u00aa ^ --Solid Tumors TGF\u03b2 Inhibitor^ --Solid Tumors TIGIT Bispecific \u00aa --Solid Tumors Additional Indications OPDIVO \u00aa --Solid Tumors --2L CRC --Pan Tumor TMB High OPDIVO \u00aa + YERVOY \u00aa --Solid Tumors --2L Metastatic Castration-Resistant Prostate Cancer OPDIVO \u00aa + CDK4/6 Inhibitor --Neoadjuvant ER+/HER2- Breast nivolumab + relatlimab --1L Stage IV NSCLC --1L/2L Hepatocellular carcinoma Investigational Compounds Anti-CTLA-4 NF Probody Therapeutic --Solid Tumors Anti-Fucosyl GM1^ --Solid Tumors Anti-IL8^ --Solid Tumors Anti-TIGIT^ --Solid Tumors BET Inhibitor (CC-90010)^ --Solid Tumors farletuzumab-ecteribulin \u00aa --Solid Tumors repotrectinib --ROS1 NSCLC --NTRK Pan Tumor Additional Indications OPDIVO \u00aa --Peri-adjuvant Muscle Invasive Urothelial Carcinoma --Adjuvant Gastric Cancer --Adjuvant HCC --Adjuvant Melanoma --1L Metastatic Castration-Resistant Prostate Cancer --Peri-adjuvant NSCLC Stage IB-IIIA Adjuvant NSCLC # OPDIVO \u00aa + YERVOY \u00aa --1L Bladder Cancer --1L HCC --1L+ MSI-High CRC h --Adjuvant RCC --Stage III Unresectable NSCLC OPDUALAG (fixed dose nivolumab + relatlimab) \u00aa --Adjuvant Melanoma --2L+ Microsatellite Stable Metastatic CRC --1L Melanoma SubQ Investigational Compounds subcutaneous nivolumab + rHuPH20 \u00aa --2L RCC --Adjuvant Melanoma ABRAXANE --Breast --Gastric --Locally Advanced or Metastatic NSCLC --Metastatic Breast Cancer --NSCLC --Pancreatic --Unresectable Pancreatic OPDIVO \u00aa --1L Metastatic Melanoma --1L Gastric --Esophageal Squamous Cell Carcinoma --1L Esophageal --Adjuvant Melanoma --Adjuvant Bladder --Adjuvant Esophageal/Gastroesophageal --Mesothelioma --Previously treated advanced RCC --Previously treated Gastric cancer (Japan, China) --Previously treated Metastatic Head & Neck --Previously treated Metastatic Melanoma --Previously treated Metastatic MSI-High CRC --Previously treated Metastatic Non-squamous NSCLC --Previously treated Metastatic Squamous NSCLC --Previously treated Metastatic Urothelial Cancer --Previously treated Esophageal Cancer --Neoadjuvant NSCLC OPDIVO \u00aa + c abozantinib \u00aa --Metastatic RCC OPDIVO \u00aa + YERVOY \u00aa --1L Metastatic Melanoma --1L Mesothelioma --1L NSCLC --1L RCC --Previously treated Metastatic MSI-High CRC --Previously treated HCC --1L Esophageal --1L Gastric OPDUALAG (fixed dose nivolumab + relatlimab) --1L Melanoma YERVOY \u00aa --Adjuvant Melanoma --Metastatic Melanoma 10 IMMUNOLOGY PHASE I PHASE II PHASE III APPROVED INDICATIONS Investigational Compounds afimetoran (TLR7/8 Inhibitor) --Cutaneous Lupus Erythematosus Anti-CD40 --Autoimmune Disease RIPK1 Inhibitor --Autoimmune Disease IL2-CD25 --Autoimmune Disease PKC\u03b8 Inhibitor --Autoimmune Disease TYK2 Inhibitor --Autoimmune Disease Additional Indications SOTYKTU (deucravacitinib) --Crohn's Disease --Alopecia Areata --Ulcerative Colitis --Discoid Lupus Erythematosus Investigational Compounds Afimetoran --Systemic Lupus Erythematosus Additional Indications SOTYKTU (deucravacitinib) --Psoriatic Arthritis --Systemic Lupus Erythematosus ZEPOSIA --Crohn\u2019s Disease Investigational Compounds cendakimab --Eosinophilic Esophagitis ORENCIA --Active Polyarticular JIA --Early Rheumatoid Arthritis --JIA Intravenous --JIA Subcutaneous --Psoriatic Arthritis --RA Auto injector --RA Intravenous --RA Subcutaneous --Acute Graft versus Host Disease SOTYKTU (deucravacitinib) --Moderate-to-Severe Psoriasis ZEPOSIA --Relapsing Multiple Sclerosis --Moderate-to-Severe Ulcerative Colitis CARDIOVASCULAR PHASE I PHASE II PHASE III APPROVED INDICATIONS Investigational Compounds Factor XIa Inhibitor \u00aa --Thrombotic Disorders Additional Indications CAMZYOS (mavacamten) --Heart Failure with Preserved Ejection Fraction (HFpEF) Investigational Compounds Cardiac Myosin Inhibitor (MYK-224) --Obstructive Hypertrophic Cardiomyopathy danicamtiv --Genetic Dilated\nrdiac Myosin Inhibitor (MYK-224) --Obstructive Hypertrophic Cardiomyopathy danicamtiv --Genetic Dilated Cardiomyopathy Additional Indications CAMZYOS (mavacamten) --Non-obstructive Hypertrophic Cardiomyopathy milvexian \u00aa --Secondary Stroke Prevention (SSP) # CAMZYOS (mavacamten) --Symptomatic Obstructive Hypertrophic Cardiomyopathy ELIQUIS \u00aa --Stroke Prevention in Atrial Fibrillation --Venous Thromboembolism Prevention --Orthopedic Surgery --Venous Thromboembolism Treatment 11 FIBROTIC DISEASES PHASE II Investigational Compounds HSP47 \u00aa --Non-Alcoholic Steatohepatitis LPA 1 Antagonist --Pulmonary Fibrosis NEUROSCIENCE PHASE I Investigational Compounds Anti-Tau \u00aa --Neuroscience BTK Inhibitor --Neuroscience eIF2b Activator \u00aa --Neuroscience FAAH/MGLL Dual Inhibitor --Neuroscience Note: Above pipeline excludes clinical collaborations \u00aa Development Partnerships: ABECMA (ide-cel): 2seventy bio; AHR: Ikena Oncology; Anti-Tau: Prothena; CAMZYOS in China, Singapore, Thailand, Macau, HK, Taiwan: LianBio; Claudin 18.2 ADC: LaNova Medicines; CD3xPSCA: Avencell; eIF2b Activator: Evotec; ELIQUIS : Pfizer; EMPLICITI : AbbVie; farletuzumab ecteribulin: Eisai; HSP47: Nitto Denko Corporation; rHuPH20: Halozyme; IDHIFA : Servier; MAGEA4/8 TCER: Immatics; milvexian: Janssen Pharmaceuticals, Inc.; OPDIVO , YERVOY , OPDUALAG : Ono; REBLOZYL : Merck; SHP2 Inhibitor: BridgeBio Pharma; TIGIT Bispecific: Agenus; PKC\u03b8 Inhibitor: Exscientia ^ Trial(s) exploring various combinations # Partner-run study The following are our registrational study readouts anticipated through 2023/2025: Oncology Hematology Asset Tumor Trial Timing Asset Disease Trial Timing Opdivo + Yervoy 1L HCC CM-9DW 2024/25 Breyanzi 3L+ CLL TRANSCEND-CLL 2023 Opdivo + Yervoy 1L+ MSI High CRC CM-8HW 2024/25 3L+ Follicular Lymphoma TRANSCEND-FL 2023 Opdivo + Yervoy Adj.",
      "score": -0.9902
    },
    {
      "sent": "8 HEMATOLOGY PHASE I PHASE II PHASE III APPROVED INDICATIONS Additional Indications OPDIVO --Hematologic Malignancies Investigational Compounds alnuctamab BCMA TCE --Relapsed/Refractory Multiple Myeloma Anti-SIRP\u03b1 -- Hematologic Malignancies BCMA ADC^ --Relapsed/Refractory Multiple Myeloma BCMA NKE --Relapsed/Refractory Multiple Myeloma BET Inhibitor (CC-90010)^ --Hematologic Malignancies CD33 NKE --Relapsed/Refractory Multiple Myeloma CD47xCD20 --Non-Hodgkin's Lymphoma CK1\u03b1 Degrader --Hematologic Malignancies GPRC5D CAR-T --Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009)^ --Relapsed/Refractory Acute Myeloid Leukemia iberdomide^ --1L Diffuse Large B-cell Lymphoma --3L+ Follicular Lymphoma --Relapsed/Refractory Non-Hodgkin Lymphoma --Large B-cell Lymphoma Additional Indications ABECMA \u00aa --1-4L+ Multiple Myeloma BREYANZI --3L+ Chronic Lymphocytic Leukemia --3L+ Follicular Lymphoma --3L+ Marginal Zone Lymphoma --3L+ Mantle Cell Lymphoma ONUREG --Low-to-Intermediate risk MDS OPDIVO \u00aa + EMPLICITI \u00aa --Relapsed/Refractory Multiple Myeloma REBLOZYL \u00aa --A-Thalassemia SubQ IDHIFA --1L Acute Myeloid Leukemia Investigational Compounds A/I CELMoD (CC-99282)^ --Relapsed/Refractory Non-Hodgkin Lymphoma BET Inhibitor (BMS-986158) --Hematologic Malignancies iberdomide --Newly-Diagnosed Multiple Myeloma Additional Indications ABECMA \u00aa --3-5L Multiple Myeloma INREBIC --MF Previously treated with Ruxolitinib REBLOZYL \u00aa --1L TD MDS Associated Anemia --1L TD MF Associated Anemia Investigational Compounds iberdomide --2L+ Multiple Myeloma mezigdomide (CC-92480) --2L+ Multiple Myeloma ABECMA --5L+ Relapsed/Refractory Multiple Myeloma --4L+ Relapsed/Refractory Multiple Myeloma BREYANZI --2L Large B-cell Lymphoma --3L+ Large B-cell Lymphoma EMPLICITI \u00aa + POMALYST/IMNOVID --Relapsed/Refractory Multiple Myeloma EMPLICITI \u00aa + REVLIMID --Relapsed/Refractory Multiple Myeloma IDHIFA -- Relapsed/Refractory Acute Myeloid Leukemia INREBIC --Myelofibrosis ONUREG --Post-Induction Acute Myeloid Leukemia Maintenance OPDIVO \u00aa --Advanced Hodgkin Lymphoma POMALYST/IMNOVID --Multiple Myeloma --Relapsed/Refractory Multiple Myeloma --AIDS related Kaposi Sarcoma --HIV-negative Kaposi Sarcoma REBLOZYL \u00aa --Transfusion-Dependent Beta-Thalassemia --MDS Previously treated with ESA REVLIMID --1L Multiple Myeloma --Mantle Cell Lymphoma --MDS --Multiple Myeloma --Previously treated Follicular Lymphoma --Relapsed/Refractory Adult T-cell Leukemia/Lymphoma SPRYCEL --1L CML --Pediatric ALL --Refractory CML 9 ONCOLOGY PHASE I PHASE II PHASE III APPROVED INDICATIONS Additional Indications OPDIVO \u00aa --Solid Tumors OPDIVO \u00aa + YERVOY \u00aa --Solid Tumors Investigational Compounds AHR Antagonist^ --Solid Tumors Anti-CCR8^ --Solid Tumors Anti-ILT4^ \u00aa --Solid Tumors AR-LDD^ --Solid Tumors Anti-NKG2A^ --Solid Tumors Claudin 18.2 ADC \u00aa --Advance Solid Tumors CD3xPSCA Bispecific --Solid Tumors DGK Inhibitor --Solid Tumors JNK Inhibitor --Solid Tumors LSD1 Inhibitor^ --Solid Tumors MAGE A4/8 TCER \u00aa --Solid Tumors SHP2 Inhibitor \u00aa ^ --Solid Tumors TGF\u03b2 Inhibitor^ --Solid Tumors TIGIT Bispecific \u00aa --Solid Tumors Additional Indications OPDIVO \u00aa --Solid Tumors --2L CRC --Pan Tumor TMB High OPDIVO \u00aa + YERVOY \u00aa --Solid Tumors --2L Metastatic Castration-Resistant Prostate Cancer OPDIVO \u00aa + CDK4/6 Inhibitor --Neoadjuvant ER+/HER2- Breast nivolumab + relatlimab --1L Stage IV NSCLC --1L/2L Hepatocellular carcinoma Investigational Compounds Anti-CTLA-4 NF Probody Therapeutic --Solid Tumors Anti-Fucosyl GM1^ --Solid Tumors Anti-IL8^ --Solid Tumors Anti-TIGIT^ --Solid Tumors BET Inhibitor (CC-90010)^ --Solid Tumors farletuzumab-ecteribulin \u00aa --Solid Tumors repotrectinib --ROS1 NSCLC --NTRK Pan Tumor Additional Indications OPDIVO \u00aa --Peri-adjuvant Muscle Invasive Urothelial Carcinoma --Adjuvant Gastric Cancer --Adjuvant HCC --Adjuvant Melanoma --1L Metastatic Castration-Resistant Prostate Cancer --Peri-adjuvant NSCLC Stage IB-IIIA Adjuvant NSCLC # OPDIVO \u00aa + YERVOY \u00aa --1L Bladder Cancer --1L HCC --1L+ MSI-High CRC h --Adjuvant RCC --Stage III Unresectable NSCLC OPDUALAG (fixed dose nivolumab + relatlimab) \u00aa --Adjuvant Melanoma --2L+ Microsatellite Stable Metastatic CRC --1L Melanoma SubQ Investigational Compounds subcutaneous nivolumab + rHuPH20 \u00aa --2L RCC --Adjuvant Melanoma ABRAXANE --Breast --Gastric --Locally Advanced or Metastatic NSCLC --Metastatic Breast Cancer --NSCLC --Pancreatic --Unresectable Pancreatic OPDIVO \u00aa --1L Metastatic Melanoma --1L Gastric --Esophageal Squamous Cell Carcinoma --1L Esophageal --Adjuvant Melanoma --Adjuvant Bladder --Adjuvant Esophageal/Gastroesophageal --Mesothelioma --Previously treated advanced RCC --Previously treated Gastric cancer (Japan, China) --Previously treated Metastatic Head & Neck --Previously treated Metastatic Melanoma --Previously treated Metastatic MSI-High CRC --Previously treated Metastatic Non-squamous NSCLC --Previously treated Metastatic Squamous NSCLC --Previously treated Metastatic Urothelial Cancer --Previously treated Esophageal Cancer --Neoadjuvant NSCLC OPDIVO \u00aa + c abozantinib \u00aa --Metastatic RCC OPDIVO \u00aa + YERVOY \u00aa --1L Metastatic Melanoma --1L Mesothelioma --1L NSCLC --1L RCC --Previously treated Metastatic MSI-High CRC --Previously treated HCC --1L Esophageal --1L Gastric OPDUALAG (fixed dose nivolumab + relatlimab) --1L Melanoma YERVOY \u00aa --Adjuvant Melanoma --Metastatic Melanoma 10 IMMUNOLOGY PHASE I PHASE II PHASE III APPROVED INDICATIONS Investigational Compounds afimetoran (TLR7/8 Inhibitor) --Cutaneous Lupus Erythematosus Anti-CD40 --Autoimmune Disease RIPK1 Inhibitor --Autoimmune Disease IL2-CD25 --Autoimmune Disease PKC\u03b8 Inhibitor --Autoimmune Disease TYK2 Inhibitor --Autoimmune Disease Additional Indications SOTYKTU (deucravacitinib) --Crohn's Disease\nr investment in our existing sites and the expansion of our manufacturing capabilities.",
      "score": -0.9883
    },
    {
      "sent": "8 HEMATOLOGY PHASE I PHASE II PHASE III APPROVED INDICATIONS Additional Indications OPDIVO --Hematologic Malignancies Investigational Compounds alnuctamab BCMA TCE --Relapsed/Refractory Multiple Myeloma Anti-SIRP\u03b1 -- Hematologic Malignancies BCMA ADC^ --Relapsed/Refractory Multiple Myeloma BCMA NKE --Relapsed/Refractory Multiple Myeloma BET Inhibitor (CC-90010)^ --Hematologic Malignancies CD33 NKE --Relapsed/Refractory Multiple Myeloma CD47xCD20 --Non-Hodgkin's Lymphoma CK1\u03b1 Degrader --Hematologic Malignancies GPRC5D CAR-T --Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009)^ --Relapsed/Refractory Acute Myeloid Leukemia iberdomide^ --1L Diffuse Large B-cell Lymphoma --3L+ Follicular Lymphoma --Relapsed/Refractory Non-Hodgkin Lymphoma --Large B-cell Lymphoma Additional Indications ABECMA \u00aa --1-4L+ Multiple Myeloma BREYANZI --3L+ Chronic Lymphocytic Leukemia --3L+ Follicular Lymphoma --3L+ Marginal Zone Lymphoma --3L+ Mantle Cell Lymphoma ONUREG --Low-to-Intermediate risk MDS OPDIVO \u00aa + EMPLICITI \u00aa --Relapsed/Refractory Multiple Myeloma REBLOZYL \u00aa --A-Thalassemia SubQ IDHIFA --1L Acute Myeloid Leukemia Investigational Compounds A/I CELMoD (CC-99282)^ --Relapsed/Refractory Non-Hodgkin Lymphoma BET Inhibitor (BMS-986158) --Hematologic Malignancies iberdomide --Newly-Diagnosed Multiple Myeloma Additional Indications ABECMA \u00aa --3-5L Multiple Myeloma INREBIC --MF Previously treated with Ruxolitinib REBLOZYL \u00aa --1L TD MDS Associated Anemia --1L TD MF Associated Anemia Investigational Compounds iberdomide --2L+ Multiple Myeloma mezigdomide (CC-92480) --2L+ Multiple Myeloma ABECMA --5L+ Relapsed/Refractory Multiple Myeloma --4L+ Relapsed/Refractory Multiple Myeloma BREYANZI --2L Large B-cell Lymphoma --3L+ Large B-cell Lymphoma EMPLICITI \u00aa + POMALYST/IMNOVID --Relapsed/Refractory Multiple Myeloma EMPLICITI \u00aa + REVLIMID --Relapsed/Refractory Multiple Myeloma IDHIFA -- Relapsed/Refractory Acute Myeloid Leukemia INREBIC --Myelofibrosis ONUREG --Post-Induction Acute Myeloid Leukemia Maintenance OPDIVO \u00aa --Advanced Hodgkin Lymphoma POMALYST/IMNOVID --Multiple Myeloma --Relapsed/Refractory Multiple Myeloma --AIDS related Kaposi Sarcoma --HIV-negative Kaposi Sarcoma REBLOZYL \u00aa --Transfusion-Dependent Beta-Thalassemia --MDS Previously treated with ESA REVLIMID --1L Multiple Myeloma --Mantle Cell Lymphoma --MDS --Multiple Myeloma --Previously treated Follicular Lymphoma --Relapsed/Refractory Adult T-cell Leukemia/Lymphoma SPRYCEL --1L CML --Pediatric ALL --Refractory CML 9 ONCOLOGY PHASE I PHASE II PHASE III APPROVED INDICATIONS Additional Indications OPDIVO \u00aa --Solid Tumors OPDIVO \u00aa + YERVOY \u00aa --Solid Tumors Investigational Compounds AHR Antagonist^ --Solid Tumors Anti-CCR8^ --Solid Tumors Anti-ILT4^ \u00aa --Solid Tumors AR-LDD^ --Solid Tumors Anti-NKG2A^ --Solid Tumors Claudin 18.2 ADC \u00aa --Advance Solid Tumors CD3xPSCA Bispecific --Solid Tumors DGK Inhibitor --Solid Tumors JNK Inhibitor --Solid Tumors LSD1 Inhibitor^ --Solid Tumors MAGE A4/8 TCER \u00aa --Solid Tumors SHP2 Inhibitor \u00aa ^ --Solid Tumors TGF\u03b2 Inhibitor^ --Solid Tumors TIGIT Bispecific \u00aa --Solid Tumors Additional Indications OPDIVO \u00aa --Solid Tumors --2L CRC --Pan Tumor TMB High OPDIVO \u00aa + YERVOY \u00aa --Solid Tumors --2L Metastatic Castration-Resistant Prostate Cancer OPDIVO \u00aa + CDK4/6 Inhibitor --Neoadjuvant ER+/HER2- Breast nivolumab + relatlimab --1L Stage IV NSCLC --1L/2L Hepatocellular carcinoma Investigational Compounds Anti-CTLA-4 NF Probody Therapeutic --Solid Tumors Anti-Fucosyl GM1^ --Solid Tumors Anti-IL8^ --Solid Tumors Anti-TIGIT^ --Solid Tumors BET Inhibitor (CC-90010)^ --Solid Tumors farletuzumab-ecteribulin \u00aa --Solid Tumors repotrectinib --ROS1 NSCLC --NTRK Pan Tumor Additional Indications OPDIVO \u00aa --Peri-adjuvant Muscle Invasive Urothelial Carcinoma --Adjuvant Gastric Cancer --Adjuvant HCC --Adjuvant Melanoma --1L Metastatic Castration-Resistant Prostate Cancer --Peri-adjuvant NSCLC Stage IB-IIIA Adjuvant NSCLC # OPDIVO \u00aa + YERVOY \u00aa --1L Bladder Cancer --1L HCC --1L+ MSI-High CRC h --Adjuvant RCC --Stage III Unresectable NSCLC OPDUALAG (fixed dose nivolumab + relatlimab) \u00aa --Adjuvant Melanoma --2L+ Microsatellite Stable Metastatic CRC --1L Melanoma SubQ Investigational Compounds subcutaneous nivolumab + rHuPH20 \u00aa --2L RCC --Adjuvant Melanoma ABRAXANE --Breast --Gastric --Locally Advanced or Metastatic NSCLC --Metastatic Breast Cancer --NSCLC --Pancreatic --Unresectable Pancreatic OPDIVO \u00aa --1L Metastatic Melanoma --1L Gastric --Esophageal Squamous Cell Carcinoma --1L Esophageal --Adjuvant Melanoma --Adjuvant Bladder --Adjuvant Esophageal/Gastroesophageal --Mesothelioma --Previously treated advanced RCC --Previously treated Gastric cancer (Japan, China) --Previously treated Metastatic Head & Neck --Previously treated Metastatic Melanoma --Previously treated Metastatic MSI-High CRC --Previously treated Metastatic Non-squamous NSCLC --Previously treated Metastatic Squamous NSCLC --Previously treated Metastatic Urothelial Cancer --Previously treated Esophageal Cancer --Neoadjuvant NSCLC OPDIVO \u00aa + c abozantinib \u00aa --Metastatic RCC OPDIVO \u00aa + YERVOY \u00aa --1L Metastatic Melanoma --1L Mesothelioma --1L NSCLC --1L RCC --Previously treated Metastatic MSI-High CRC --Previously treated HCC --1L Esophageal --1L Gastric OPDUALAG (fixed dose nivolumab + relatlimab) --1L Melanoma YERVOY \u00aa --Adjuvant Melanoma --Metastatic Melanoma 10 IMMUNOLOGY PHASE I PHASE II PHASE III APPROVED INDICATIONS Investigational Compounds afimetoran (TLR7/8 Inhibitor) --Cutaneous Lupus Erythematosus Anti-CD40 --Autoimmune Disease RIPK1 Inhibitor --Autoimmune Disease IL2-CD25 --Autoimmune Disease PKC\u03b8 Inhibitor --Autoimmune Disease TYK2 Inhibitor --Autoimmune Disease Additional Indications SOTYKTU (deucravacitinib) --Crohn's Disease --Alopecia Areata --Ulcerative Colitis --Dis\nacturing capabilities.",
      "score": -0.9883
    }
  ],
  "forward_snippets": [
    "We continue to operate in one segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.",
    "We expect that our acquisitions of MyoKardia in 2020 and Turning Point in 2022 will further position us as a leading biopharmaceutical company, expanding our precision oncology and cardiovascular portfolios with several near-term assets and additional external partnerships.",
    "Our focus as a biopharmaceutical company is on discovering, developing and delivering transformational medicines for patients facing serious diseases in areas where we believe that we have an opportunity to make a meaningful difference: oncology, hematology, immunology, cardiovascular and neuroscience.",
    "Our priorities are to continue to renew and diversify our portfolio through launching our new product portfolio, advancing our early, mid and late-stage pipeline, and executing disciplined business development.",
    "We remain committed to strengthening our balance sheet and returning capital to shareholders."
  ]
}